Spearhead 1 Study for Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Exclusion Criteria

• Have a specific genetic marker called HLA-A*02:05.
• Have received or plan to receive certain treatments before the study, such as:
  • Chemotherapy or tyrosine kinase inhibitors (e.g., pazopanib).
  • Immune therapies, including monoclonal antibodies or checkpoint inhibitors.
  • Anti-cancer vaccines or gene therapy using certain vectors.
  • Corticosteroids or other immunosuppressive therapies.
  • Participation in other investigational treatments or clinical trials.
  • Allogeneic stem cell transplant.
  • Radiation therapy to the target cancer areas.
  • Major surgery.
• Have a history of allergic reactions to similar drugs used in the study.
• Have a history of autoimmune or immune-mediated diseases.
• Have cancer that has spread to the brain or spinal cord.
• Have another type of cancer that is not in complete remission.
• Have significant heart disease.
• Have uncontrolled illnesses.
• Have active infections with HIV, hepatitis B, hepatitis C, or human T cell leukemia virus.
• Are pregnant or breastfeeding.

Note: Other exclusion criteria may apply as defined by the study protocol.